Pharmacological Treatment of Osteoporosis After Fragility Fracture

A Comprehensive, Evidence-Based Guide for Clinicians

---

Meta description (SEO)

Evidence-based guide to pharmacological osteoporosis treatment after fragility fracture. Covers antiresorptives, anabolic therapy, sequencing, safety, and monitoring.

---

Focus keywords

Osteoporosis treatment after fragility fracture
Pharmacological management of osteoporosis
Anabolic vs antiresorptive therapy
Hip fracture osteoporosis treatment
Secondary fracture prevention

---

Introduction

A fragility fracture represents established osteoporosis, regardless of bone mineral density (BMD). Patients sustaining a low-trauma fracture face a markedly increased risk of subsequent fractures, particularly within the first 12–24 months—a period described as imminent fracture risk.

Modern osteoporosis management has therefore shifted from a BMD-centric approach to a fracture-first strategy, emphasising early pharmacological intervention to prevent secondary fractures, reduce mortality, and preserve independence.

This article provides a comprehensive, guideline-aligned overview of pharmacological osteoporosis treatment following fragility fracture, with practical relevance for routine clinical practice.

---

1. Indications for Pharmacological Therapy After Fragility Fracture

All adults aged ≥50 years who sustain a low-energy fracture (hip, vertebra, distal radius, proximal humerus, pelvis) should be considered at high or very high fracture risk.

Key principles

• Treatment is indicated irrespective of BMD

• DXA scanning should not delay therapy

• The greatest absolute fracture risk reduction occurs when treatment is initiated soon after fracture

Current international guidance supports prompt pharmacological treatment following a fragility fracture.

---

2. Antiresorptive Agents

Antiresorptive therapies reduce bone turnover by inhibiting osteoclast-mediated bone resorption and form the backbone of osteoporosis treatment.

---

2.1 Bisphosphonates (First-Line Therapy)

Common agents and dosing

Clinical benefits

• Vertebral fracture risk reduction ~40–70%

• Hip fracture risk reduction ~40–50%

• Demonstrated mortality benefit following hip fracture (zoledronic acid)

Key considerations

• Avoid if eGFR <30–35 mL/min

• Oral agents require strict administration instructions

• Acute phase reaction may occur with IV therapy and is usually self-limiting

---

2.2 Denosumab

Dose
60 mg subcutaneous injection every 6 months

Indications

• Intolerance or contraindication to bisphosphonates

• Advanced renal impairment

• Poor adherence to oral therapy

Critical safety principle

Denosumab must not be discontinued without follow-on antiresorptive therapy due to the risk of rapid bone loss and rebound vertebral fractures.

---

3. Anabolic and Dual-Action Therapies

---

3.1 Patients Suitable for Anabolic-First Therapy

Patients at very high fracture risk, including:

• Recent hip or vertebral fracture

• Multiple fragility fractures

• T-score ≤ −2.5 with fracture

• Fracture occurring while on antiresorptive therapy

---

3.2 Available Agents

Clinical advantages

• Rapid increases in BMD

• Superior vertebral fracture risk reduction

• Effective after antiresorptive failure

Romosozumab caution

• Contraindicated in patients with recent myocardial infarction or stroke

• Cardiovascular risk assessment is mandatory prior to initiation

---

4. Treatment Sequencing: A Critical Determinant of Outcomes

Therapeutic efficacy is sequence-dependent.

Optimal strategy for very high-risk patients

1. Anabolic therapy first (12–24 months)

2. Long-term antiresorptive therapy to maintain gains

Suboptimal strategy

• Prolonged antiresorptive therapy prior to anabolic agents may attenuate anabolic response.

---

5. Duration of Therapy and Drug Holidays

Bisphosphonates

• Reassess after 3–5 years

• Consider drug holiday if fracture risk becomes low–moderate

Denosumab

• No drug holidays

• Requires planned transition to bisphosphonate therapy if discontinued

Anabolic agents

• Lifetime exposure limited (1–2 years)

• Must be followed by antiresorptive therapy

---

6. Monitoring and Follow-Up

Clinical monitoring

• Adherence and persistence

• Interval fractures

• Falls risk and secondary causes

Investigations

• DXA every 1–2 years (earlier only if clinically indicated)

• Bone turnover markers in selected cases

• Calcium and vitamin D levels prior to injectable therapy

---

7. Safety and Adverse Effects

Overall, the benefits of pharmacological therapy substantially outweigh the risks in patients with fragility fractures.

---

8. Adjunctive Measures (Essential but Not Sufficient Alone)

• Calcium: 1,000–1,200 mg/day (diet plus supplements)

• Vitamin D: 600–800 IU/day (higher doses if deficient)

• Falls prevention strategies

• Resistance and balance training

• Medication review

Calcium and vitamin D supplementation do not replace pharmacological therapy after fracture.

---

Practical Take-Home Messages

• A fragility fracture is a treatment-triggering event

• Early therapy reduces refracture rates and mortality

• Anabolic-first strategies provide superior outcomes in very high-risk patients

• Denosumab discontinuation must always be planned

• Treatment sequencing is as important as drug selection

---

Conclusion

Pharmacological osteoporosis treatment following fragility fracture is central to effective secondary fracture prevention. Contemporary evidence supports early, risk-stratified therapy, with increasing emphasis on anabolic-first strategies for those at highest risk.

Embedding these principles into fracture liaison services, orthogeriatric pathways, and routine clinical practice is essential to closing the osteoporosis treatment gap and improving long-term patient outcomes.

References

1. Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3–44. doi:10.1007/s00198-018-4704-5

2. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. doi:10.1007/s00198-014-2794-2

3. Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1595–1622. doi:10.1210/jc.2019-00221

4. Compston J, Cooper A, Cooper C, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43. doi:10.1007/s11657-017-0324-5

5. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809–1822. doi:10.1056/NEJMoa067312

6. Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–1809. doi:10.1056/NEJMoa074941

7. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765. doi:10.1056/NEJMoa0809493

8. Anastasilakis AD, Polyzos SA, Makras P. Clinical features and management of rebound-associated vertebral fractures after denosumab discontinuation. Bone. 2017;105:11–17. doi:10.1016/j.bone.2017.08.003

9. Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis. JAMA. 2016;316(7):722–733. doi:10.1001/jama.2016.11136

10. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434–1441. doi:10.1056/NEJM200105103441904

11. Saag KG, Petersen J, Brandi ML, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–1427. doi:10.1056/NEJMoa1708322

12. Cosman F, Crittenden DB, Adachi JD, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–1543. doi:10.1056/NEJMoa1607948

13. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–420. doi:10.1056/NEJMoa1305224

14. Johansson H, Siggeirsdóttir K, Harvey NC, et al. Imminent risk of fracture after fracture. Osteoporos Int. 2017;28(3):775–780. doi:10.1007/s00198-016-3868-0

15. Kanis JA, Harvey NC, Johansson H, et al. A decade of FRAX: how has it changed the management of osteoporosis? Aging Clin Exp Res. 2020;32(2):187–196. doi:10.1007/s40520-019-01432-3